1	Efficacy of Intrawound Vancomycin in Prevention of Periprosthetic Joint Infection					
2	After Primary Total Knee Arthroplasty					
3	A Prospective Double-Blinded Randomized Control Trial					
4						
5 6	Author	rs:				
7	1.	Praharsha Mulpur ¹				
8 9		Consultant Orthopaedic and Joint Replacement Surgeon <u>Praharshamulpur9@gmail.com</u>				
9 10		<u>Pranarsnamurpur9(@gman.com</u>				
10	2.	Tarun Jayakumar ¹ [Corresponding Author]				
12		Registrar, Arthroplasty				
13		tarunjaykumar@gmail.com				
14						
15	3.	Ramakanth R Yakkanti ²				
16		MD, Rothman Orthopaedic Institute				
17		<u>yakkanti1@gmail.com</u>				
18	_					
19	4.	Aditya Apte ¹				
20		Research Fellow, Division of Arthroplasty				
21 22		<u>dradityaapte@gmail.com</u>				
23	5.	Kushal Hippalgaonkar ¹				
24	01	Consultant Orthopaedic and Joint Replacement Surgeon				
25		kushalhippal@gmail.com				
26						
27	6.	Adarsh Annapareddy ¹				
28		Consultant Orthopaedic and Joint Replacement Surgeon				
29		dr.adarshannapareddy@gmail.com				
30	7					
31 32	7.	A B Suhas Masilamani ¹ Consultant Orthopaedic and Joint Replacement Surgeon				
33		drsuhas09@gmail.com				
34		<u>ursunaso (agman.com</u>				
35	8.	A V Gurava Reddy ¹				
36		Consultant and Chief Orthopaedic and Joint Replacement Surgeon				
37		guravareddy@gmail.com				
38						
39		Affiliations:				
40		1- Sunshine Bone and Joint Insitute, KIMS-Sunshine Hospitals, Hyderabad, India				
41		2- Rothman Orthopedic Institute, Philadelphia				
42						
43	NOTE: T	his preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.				

44 ABSTRACT

45

Introduction: Peri-prosthetic Joint Infection (PJI) after total knee arthroplasty (TKA) is a 46 47 devastating complication. Intra-wound vancomycin powder has been shown to reduce infection rates in spine surgery. Previous studies on the efficacy of local vancomycin powder 48 49 in hip or knee arthroplasty are mostly retrospective case series. The aim of this prospective 50 RCT was to evaluate the efficacy and safety of intrawound vancomycin in preventing PJI 51 after primary TKA. 52 Methods: This study was a National Trial Registry-approved RCT of patients undergoing primary TKA. 1022 patients were randomized to the study group (n=507, received 2g 53 54 intrawound vancomycin powder before arthrotomy closure) and control groups (n=515, no local vancomycin). The minimum follow-up was 12-months. The primary outcome was PJI 55 rate. Secondary outcomes included surgical site infection (SSI) rates, incidence of revision 56 57 for PJI/SSI, and incidence of wound complications. High-risk groups (Obesity and Diabetes) in both cohorts were also evaluated. 58 59 Results: The overall infection rate in 1022 patients was 0.66%. There was no significant difference in PJI rate in the study group (0.2%) versus the control group (0.58%), p=0.264. 60 61 Reoperation rates in the study group (N=4;0.78%) and Control (N=5;0.97%) and SSI rates in the study (N=1;0.2%) and control groups (N=2;0.38%) were comparable. The Vancomycin 62 cohort however demonstrated a significantly higher number of minor wound complications 63 (n=67;13.9%) compared to the control group (n=39;8.4%, p<0.05). There was no difference 64 65 in PJI/SSI rates or minor surgical complications among high-risk groups and no cases of nephrotoxicity were reported in the study. 66 Conclusion: Intra-wound vancomycin powder does not appear to reduce PJI/SSI rate in 67 primary total knee arthroplasties, including high-risk groups. Although safe from a renal 68 69 perspective, intra-wound vancomycin was associated with an increase in postoperative 70 aseptic wound complications such as persistent wound drainage. Intra-wound vancomycin 71 may not be effective in reducing the rate of PJI in primary TKA. 72 73 Keywords: Infection; Arthroplasty; Knee; Prosthetic Joint Infection; Surgical site infection 74 75 76 77

78 INTRODUCTION

79 There is an ever-increasing global burden of primary total knee and total hip arthroplasty 80 procedures, with a significant increase in surgery numbers projected by the year 2030(1-3). 81 With increasing numbers of primary total joint replacement surgeries, healthcare systems 82 across the world are poised to handle an increased burden of revision arthroplasty cases. 83 Worldwide, the reported incidence of PJI after total joint replacement is around 0.8-1.5%, with a 1-2% PJI risk after TKA (4-6). 84 85 86 Periprosthetic joint infection (PJI) is one of the most common indications for revision after 87 TKA (7-9) posing a significant burden to the healthcare system (10,11). There has been increasing interest in the use of local antibiotic powder in the joint before closure to prevent 88 89 local contamination and biofilm formation. The use of intrawound vancomycin in preventing surgical site infections is well documented in spine surgery (12–14). There are some 90

91 published reports of the benefits of local vancomycin powder used in surgeries of the elbow,

foot and ankle surgery (15,16). However, its use and clinical benefit in total knee arthroplastyis debatable.

94

95 The main postulated advantages of using local vancomycin powder are its relatively cheap

96 cost, favourable bacterial spectrum (MRSA, coagulase-negative staphylococci), high local

97 concentrations without systemic adverse effects (17,18). Systematic reviews and meta-

analyses on studies evaluating the use of vancomycin in primary total knee or hip arthroplasty

99 reported low-quality evidence with a high risk of study bias (19,20). No randomized control

trial (RCT) has evaluated the efficacy of local vancomycin powder in primary TKA.

101

The primary objective of this study was to evaluate the efficacy of intra-wound vancomycin
in reducing SSI or PJI rates in patients undergoing primary total knee arthroplasty. Secondary
objectives include the evaluation of wound-healing-related complications, incidence of
nephrotoxicity, and the influence of diabetes and obesity on outcomes.

106

107

108 Methods

109 This is an Institutional Review Board (IRB) approved prospective randomized, controlled

trial (RCT), and was prospectively registered with the National Central Trial Registry

111 (CTRI/2021/02/031310). This is a single-centre RCT of patients from a high-volume tertiary

112 care institute, who underwent primary total knee arthroplasty (TKA) for primary

113 osteoarthritis of the knee, between January 2021 and February 2022. The RCT was a parallel-

arm trial with a 1:1 allocation of patients into study and control groups. Study group patients

115 receive intra-articular 2g Vancomycin antibiotic powder before arthrotomy closure, control

116 group patients did not receive local vancomycin powder. The trial was conducted following

- the guidelines of the Declaration of Helsinki on scientific studies involving human subjects.
- 118

All adult patients with primary osteoarthritis of the knee, consenting to primary manual jig-

120 based TKA were eligible for recruitment in this trial. This includes patients with primary OA,

121 with either varus or valgus deformity of the knee. Patients were excluded from the trial if

they met any of the following exclusion criteria- refusal to participate in the trial, intra-

123 operative findings suggestive of inflammatory arthropathy or non-specific synovitis, previous

124 knee surgeries, history of intra-articular knee injections within 3 years before surgery, known

allergy to Vancomycin, and if they were known cases of chronic immunosuppression

126 (secondary to human immuno-deficiency virus-HIV, malignancy or post-solid organ

transplant). Patients who used antibiotics for any cause, within 1-month leading up to surgery

- 128 were also excluded from the trial.
- 129

130 There were a total of 1208 eligible patients who underwent primary TKA during the study period (January 2021 to January 2022). 56 patients declined to participate in the trial and a 131 132 further 24 patients were excluded due to exclusion criteria (12 patients used antibiotics for Urinary tract infections, 8 patients with recent intra-articular knee visco-supplementation 133 134 injections and 4 patients with chronic immunosuppression). After exclusions, 1128 patients were randomized to the study and control groups. 34 patients were excluded from the final 135 136 data analysis after randomization (16 deaths in the follow-up period, 18 cases with intra-137 operative findings suggestive of inflammatory arthropathy or non-specific synovitis).

138

The final study cohorts consisted of 549 patients in the study group and 545 patients in the Control group. There was a loss to follow-up of 42 patients (8%) in the study group and 30 patients (5.76%) in the control group, Final analysis included 507 subjects in the study group and 515 subjects in the control group.

143

144 Eligible trial participants undergoing primary total knee arthroplasty were randomized (1:1

allocation by computer randomization) to receive either normal saline lavage with (study

group) or without (control group) intra-articular 2g Vancomycin powder prior to arthrotomy
closure. All patients were operated on at the same institute, in laminar flow operating rooms.
Except for the use of vancomycin powder in the surgical wound, the operating procedures
and peri-operative protocols were common to both groups. The patients are blinded and
unaware of the assigned groups and follow-up evaluation for infection related complications

- 151 was performed by a blinded observer.
- 152

All cases in this trial received a standard antibiotic prophylaxis protocol, which includes 3 153 154 peri-operative intra-venous doses of 1.5g of Cefuroxime. The first dose was administered 1 155 hour before the skin incision and 2 doses were administered 8 hours and 24 hours after surgery. None of the cases in this trial received prolonged Oral antibiotic use after surgery. 156 Skin preparation at the time of surgery was done with Chlorhexidine skin scrub (3M, 157 Avagard 4% Chlorhexidine Scrub). TKA was performed through a medial para-patellar 158 159 approach in all cases, under a tourniquet. Tourniquet was inflated from the time of the incision till the cement was fully-set after final implantation. The knee joint was irrigated 160 161 with a total of 3 L of normal saline with pulse lavage before and after cementing of the implant. All cases received bone cement without antibiotic impregnation (Palacos/ Stryker 162 163 Simplex low-viscosity cement). Patella was not resurfaced in any case, in either group. After 164 deflation of the tourniquet and haemostasis of bleeding vessels, the study group received 2g vancomycin powder, which was placed into the medial and lateral joint gutters and 165 166 arthrotomy closed with No.2 Vicryl in an interrupted fashion followed by a continuous 167 STRATAFIX (Barbed-PDS) running stitch. Suction drains were not used in any case.

168

169 Post-operative blood investigations (Renal parameters, CBP) were obtained 24 hours after the

170 surgery. In all cases, wound dressing was changed 24 hours later in the PACU, with

171 MEPILEX surgical dressing (Mepilex Border Post-op, Mölnlycke, Göteborg, Sweden).

172 Patients in both groups received uniform rehabilitation with assisted walking and range of

173 motion exercises on the first postoperative day. Deep vein thrombosis prophylaxis was

174 common with low-Molecular weight heparin (LMWH) in the immediate postoperative period

and Oral Apixaban 2.5mg twice daily for 14 days following surgery. Surgical staple removal

is done between Day 14 and Day 21 after surgery. Staple removal after 21 days is considered

to be "Delayed staple/clip removal". Patients were routinely followed up at 2 weeks, 4 weeks,

178 3 months and 6 months and 12 months after surgery.

179

180 Based on the criteria identified by Parvizi et al (21), early peri-prosthetic joint infection was

- 181 defined as an infection diagnosed within 90 days of surgery. Infection was diagnosed based
- 182 on the MSIS criteria and the 2018 Definition of Periprosthetic Hip and Knee Infection
- 183 consisting of 2 positive cultures (from an aspirate and/or at the time of debridement for PJI or
- 184 SSI), elevated serum ESR, CRP and elevated white cell counts in synovial fluid aspirates
- 185 (>10,000 cells/mm³), PMN percentage greater than 90% in the synovial aspirate(21,22).
- 186 Cases of possible infections based on the 2018 ICM (International Consensus Meeting)
- 187 scoring system were confirmed based on the findings of pus in aspirate and intra-operative
- 188 findings of purulence.
- 189 Surgical site infections and deep peri-prosthetic joint infections were considered major
- 190 surgical complications, necessitating re-operation. Minor complications included delayed
- 191 wound healing with or without dehiscence, delayed surgical staple removal, and stitch/suture
- abscess (based on CDC Guidelines) necessitating oral antibiotic use. Persistent wound
- 193 drainage was defined as, wound drainage beyond 72-hours necessitating surgical dressing
- 194 change, based on previous definitions of persistent wound drainage (21,23).
- Patients were also monitored in the peri-operative period for medical complications of
 Myocardial infarction, DVT/PE, CVA and nephrotoxicity secondary to the use of
- 197 vancomycin.
- 198

199 Statistical analysis

- 200 Xu et al conducted a systematic review and meta-analysis of intra-wound vancomycin
- 201 powder used in primary total knee and hip arthroplasty(24). This meta-analysis concluded
- that a minimum sample of 1000 patients was required for analysis, to conform to a decrease
- of PJI rate from 2.74% to 1% in control versus study groups, with a power of 80% and 5%
- significance level. Assuming a drop-out rate of 10%, we recruited over 1100 eligible subjects
- for trial participation and randomization. Statistical analysis was performed using a 2-tailed
- 206 or independent samples t-test for continuous data parameters. The Chi-squared test or
- 207 Fisher's Exact test was used for categorical data parameters. Statistical analysis was
- 208 performed using SPSS Version 24 (International Business Machines- IBM, Armonk, NY).
- Assuming a power of 80% and 95% confidence intervals, a p-value less than 0.05 was
- 210 considered significant.
- 211
- 212

213 Results

A total of 1022 patients were included in the final statistical analysis, with 507 patients in the study group and 515 patients in the control group, after exclusions, loss to follow-up and deaths. Demographic variables and baseline characteristics such as comorbidities, BMI, ASA grading, and CCI grading were comparable between both groups and summarised in **Table.1**. The mean tourniquet times and mean haemoglobin drop after surgery were also comparable between both groups. The CONSORT Flowchart of participant recruitment is shown in

220 *Figure.1*

221

222 Infection rates

223 The overall infection rate in the study population was 0.66%. Periprosthetic joint infection

(PJI) was seen in 1 patient (0.19%) in the study group and 3 patients (0.58%) in the control

group, and the difference was not statistically significant. Surgical site infection (SSI) was

reported in 1 (0.19%) patient in the study group and 2 patients (0.38%) in the control group. 2

227 patients in the study group had periprosthetic fractures of the distal femur during the follow-

228 up period and underwent ORIF. All complications in the trial are summarized in Table 2.

229

230 Peri-prosthetic Joint Infections (PJI)

In the study group, one patient (0.19%) underwent DAIR for a culture-negative PJI, 4 weeks

after surgery. This patient had elevated serum ESR, CRP and White cell counts and frank pus

aspirated from the joint before DAIR. In the control group, 3 patients (0.58%) underwent

234 DAIR, of which one patient had Staphylococcus aureus isolated, and later went on to have a

235 2-stage revision due to the persistence of infection. The other two patients had culture-

and underwent DAIR.

237

238 Surgical Site Infections (SSI)

239 One patient in the study group presented with an early SSI, with Staphylococcus epidermidis

the pathogenic organism isolated. This patient presented with persistent wound discharge

241 which was managed with superficial wound debridement and secondary closure and iv

antibiotics. 2 patients in the control group developed SSI, for which one patient underwent

243 debridement and secondary closure for local wound necrosis and the other patient developed

- septic shock and Multi-Organ Dysfunction (MODS) following wound debridement at an
- 245 outside hospital, requiring hospitalization and intravenous antibiotics. The major
- complications of PJI and SSI are summarized in Table 3.

247

248 Re-operation Rates

- 249 Re-operation rates between both groups were found to be statistically comparable, with 4
- 250 0.78%) patients in the study group (1-PJI, 1-SSI, 2-Periprosthetic fracture) versus 5 cases
- 251 (0.97%) in the control group (3-PJI, 2-SSI). (Table 2)
- 252

253 Wound Complications

- 254 The use of vancomycin was associated with a significantly higher number of minor wound
- complications in the study group (n=67; 13.9%) compared to the control group (n=39; 8.4%,
- p < 0.05). Aseptic wound complications such as wound soakage, maceration and stitch abscess
- 257 were managed with regular dressings without any additional oral or intravenous antibiotic
- use. Delayed suture removal (>3 weeks) was found to be similar in both groups and not
- 259 statistically significant. (Table 2)
- 260

261 Sub-group Analysis

- We evaluated differences in complication rates amongst patients of both groups based on
 BMI and compared diabetics with non-diabetics. There was no difference in PJI/SSI rates or
 minor surgical complications among high-risk groups, Diabetics versus non-diabetics, (Table
- 265 4) and high BMI vs normal BMI (Tables 5 & 6).
- 266

267 Systemic Complications and Mortality

- The use of intra-wound vancomycin was not associated with acute kidney injury (defined as an increase in serum creatinine levels by more than 0.3mg/dl within 48 hours)(25).
- A total of 16 patients expired in the follow up period (10 patients in the study group versus 6
- 271 patients in the control group. One patient in the control group developed DVT with
- 272 Pulmonary embolism 45 days post-surgery and expired. Other patients expired secondary to
- non-surgical factors (1 patient secondary to complications of CKD in the control group, 1
- 274 patient with Pleural effusion, 4 patients expired after treatment for trauma unrelated to the
- 275 prior knee arthroplasty). No cases of CVA, AMI, Nephrotoxicity, Ototoxicity or anaphylactic
- 276 reactions were observed or documented in the post-operative 90-day follow-up period.
- 277
- 278
- 279
- 280

281 Discussion

282 This randomised control trial did not demonstrate any additional clinical benefit of topical or

- intra-wound vancomycin powder in preventing SSI/PJI in patients undergoing primary total
- 284 knee arthroplasty. On the contrary, there was a significant increase in wound healing
- complications in the study group, with a significantly higher incidence of persistent wound
- 286 discharge and stitch abscess compared to the control group.
- 287

PJI after TKA bears a heavy toll on the patient and contributes to the economic burden on the healthcare systems (6,11). The use of local antibiotic powder in orthopaedic surgery is not new, with several reports of benefits in spine surgery (12–14,19,26). However, most of these studies were retrospective and non-randomised. Tubaki et al published the only RCT on the use of vancomycin in spine surgery and concluded that there was no difference in infection

- rates with the use of vancomycin (27).
- 294

The role of topical or intra-wound vancomycin in primary total knee arthroplasty is
undecided, with studies both supporting and refuting the efficacy of vancomycin in reducing
post-operative PJI rates.

298

Heckman et al (28) published a meta-analysis and systematic review of intra-wound 299 300 vancomycin in total hip and knee arthroplasty with evidence demonstrating lower infection rates with the use of vancomycin. However, all 6 studies included in the meta-analysis were 301 302 retrospective case series with Level-III evidence. Xu H et al published their meta-analysis of 4607 patients reporting a reduced PJI rate with the use of vancomycin but a higher incidence 303 of local wound complications and superficial surgical site infections (24). Our trial had 304 similar findings of a higher incidence of minor complications such as persistent wound 305 306 drainage and stitch abscesses in the study group.

307

Although previous studies attempted to evaluate the efficacy of intra-wound vancomycin, most were either underpowered due to the relatively low incidence of PJI, or suffered from low quality evidence secondary to retrospective study designs or lack of randomization. To the best of our knowledge, this study is the first prospective randomized control trial on the use of intra-wound vancomycin in primary TKA.

- 313
- 314

Effect of intra-wound vancomycin on PJI/SSI 315

316	In this trial, the use of intra-wound vancomycin powder in primary TKA failed to show a
317	reduction in the incidence of PJI/SSI. Previously published studies also showed no decrease
318	in the incidence of PJI with local vancomycin use (29,30)(31). On the contrary, Winkler et al
319	showed a statistically significant decrease in PJI in primary TKA. In the same study,
320	however, there was only a trend towards decreased PJI with local antibiotic administration in
321	THA and revision TKA/THA without statistical significance (32). The main limitation of this
322	report was the retrospective study design and heterogeneity of the study population which
323	included both primary and revision knee or hip arthroplasty, with varying intra-operative
324	protocols.
325	
326	Most studies reporting reduced infection rates with the use of intra-wound vancomycin were
327	retrospective (33,34). Otte et al in their study of 1640 patients showed that 1g of intra-wound
328	vancomycin significantly reduced the incidence of PJI in both primary and revision scenarios
329	for both hips and knees (35). Patel et al also reported that intra-wound vancomycin was both
330	safe and effective in reducing rates of early PJI in both primary hip and knee arthroplasties
331	(36).

331

332

A meta-analysis by Peng et al, which included 4512 patients in 9 studies, also recommended 333 the use of vancomycin powder to reduce the incidence of PJI without modifying the bacterial 334 335 spectrum (37). A recent systematic review of 3371 patients did not demonstrate a significant 336 reduction in PJI in patients receiving vancomycin (38). This was similar to the findings of the 337 current trial.

338

This trial also showed a statistically significant increase in minor wound complications such 339 as persistent wound drainage and stitch abscesses with the use of vancomycin. However, this 340 341 should be interpreted with caution, as the trial may be underpowered to evaluate minor 342 complications. Similar wound complications were also reported in previously published 343 studies (20,24,26,33). The exact cause of this has not been determined but has been attributed to the crystalline nature of the vancomycin salt, low pH of the vancomycin solution or as a 344 345 part of the body's inflammatory response to the vancomycin which leads to seroma formation 346 and subsequent wound complications (39). The aseptic wound complications in our study 347 were managed using repeated sterile wound dressings without the routine use of antibiotics.

- Management of persistent wound drainage and breakdown can vary with some institutesopting for wound debridement and secondary closure in the operation theatre (20,33).
- 350

351 Use of intra-wound vancomycin in diabetics and other high-risk groups

- 352 The use of vancomycin did not appear to significantly influence SSI/PJI rates in diabetics
- 353 versus non-diabetics in the study population. There was no difference in outcomes based on
- the BMI classification of patients.
- 355
- 356 The strengths of this study include the prospective randomised study design, the trial
- 357 performed at a single high-volume arthroplasty institute with a standardised protocol
- followed in all cases and a very low attrition during the follow-up period.
- 359

This study has some limitations. Firstly, this study is powered to detect a 1.7% difference in 360 361 the PJI rates between the study and control groups. The trial is not adequately powered to detect smaller differences in PJI rates. The study may be underpowered for the minor 362 363 complications such as prolonged wound drainage and delayed wound healing. This calls for large-volume multi-centre RCTs, with uniform protocols in peri-operative management. 364 365 Registry-based studies will be high-powered but subject to bias due to varying institutional protocols in the asepsis procedures and antibiotic policies. Secondly, the results in this trial 366 are based on data from a single institute. Although the surgical technique, aseptic precautions 367 and antibiotic policy have been standardised across the study population, the findings may 368 369 not be generalizable to other institutions dissimilar to ours. Other limitations include sub-370 analysis of other factors potentially contributing to PJI rate such as smoking or individual comorbidities, which were not independently evaluated. 371

372

373 CONCLUSION

Intra-wound vancomycin powder application does not appear to reduce PJI/SSI rate in
primary total knee arthroplasties, including in high-risk groups. The use of intra-wound
vancomycin was associated with an increase in postoperative aseptic wound complications
such as persistent wound drainage. Intra-wound vancomycin may not be effective in reducing
the rate of PJI in primary TKA.

- 379
- 380
- 381

382 REFERENCES

- Ackerman IN, Bohensky MA, Zomer E, Tacey M, Gorelik A, Brand CA, et al. The
 projected burden of primary total knee and hip replacement for osteoarthritis in
- Australia to the year 2030. BMC Musculoskelet Disord. 2019 Feb;20(1):90.
- Kim TW, Kang S-B, Chang CB, Moon S-Y, Lee Y-K, Koo K-H. Current Trends and
 Projected Burden of Primary and Revision Total Knee Arthroplasty in Korea Between
 2010 and 2030. J Arthroplasty. 2021;36(1):93–101.
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip
 and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am.
 2007 Apr;89(4):780–5.
- Springer BD, Cahue S, Etkin CD, Lewallen DG, McGrory BJ. Infection burden in total
 hip and knee arthroplasties: an international registry-based perspective. Arthroplast
 today. 2017 Jun;3(2):137–40.
- Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint
 infection. Lancet (London, England). 2016 Jan;387(10016):386–94.
- Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and
 knee arthroplasty in the United States. J Arthroplasty. 2008 Oct;23(7):984–91.
- Clohisy JC, Calvert G, Tull F, McDonald D, Maloney WJ. Reasons for revision hip
 surgery: a retrospective review. Clin Orthop Relat Res. 2004 Dec;(429):188–92.
- 401 8. Fehring TK, Odum S, Griffin WL, Mason JB, Nadaud M. Early failures in total knee
 402 arthroplasty. Clin Orthop Relat Res. 2001 Nov;(392):315–8.
- 403 9. Vessely MB, Whaley AL, Harmsen WS, Schleck CD, Berry DJ. The Chitranjan
 404 Ranawat Award: Long-term survivorship and failure modes of 1000 cemented
 405 condylar total knee arthroplasties. Clin Orthop Relat Res. 2006 Nov;452:28–34.
- 406 10. Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, et al.
- 407 Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in
 408 the United States. J Arthroplasty. 2021 May;36(5):1484-1489.e3.
- 409 11. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of
 410 periprosthetic joint infection in the United States. J Arthroplasty. 2012 Sep;27(8
 411 Suppl):61-5.e1.
- 412 12. Dodson V, Majmundar N, Swantic V, Assina R. The effect of prophylactic
 413 vancomycin powder on infections following spinal surgeries: a systematic review.
 414 Neurosurg Focus. 2019 Jan;46(1):E11.
- 415 13. Caroom C, Tullar JM, Benton EGJ, Jones JR, Chaput CD. Intrawound vancomycin

416		powder reduces surgical site infections in posterior cervical fusion. Spine (Phila Pa
417		1976). 2013 Jun;38(14):1183–7.
418	14.	Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA. The use of
419		vancomycin powder in modern spine surgery: systematic review and meta-analysis of
420		the clinical evidence. World Neurosurg. 2015 May;83(5):816–23.
421	15.	Yan H, He J, Chen S, Yu S, Fan C. Intrawound application of vancomycin reduces
422		wound infection after open release of post-traumatic stiff elbows: a retrospective
423		comparative study. J shoulder Elb Surg. 2014 May;23(5):686-92.
424	16.	Wukich DK, Dikis JW, Monaco SJ, Strannigan K, Suder NC, Rosario BL. Topically
425		Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic
426		Patients Undergoing Foot and Ankle Surgery. Foot ankle Int. 2015 Sep;36(9):1017-24.
427	17.	Johnson JD, Nessler JM, Horazdovsky RD, Vang S, Thomas AJ, Marston SB. Serum
428		and Wound Vancomycin Levels After Intrawound Administration in Primary Total
429		Joint Arthroplasty. J Arthroplasty. 2017 Mar;32(3):924-8.
430	18.	Burdon DW. Principles of antimicrobial prophylaxis. World J Surg. 1982
431		May;6(3):262–7.
432	19.	Fleischman AN, Austin MS. Local Intra-wound Administration of Powdered
433		Antibiotics in Orthopaedic Surgery. J bone Jt Infect. 2017;2(1):23-8.
434	20.	Hanada M, Nishikino S, Hotta K, Furuhashi H, Hoshino H, Matsuyama Y. Intrawound
435		vancomycin powder increases post-operative wound complications and does not
436		decrease periprosthetic joint infection in primary total and unicompartmental knee
437		arthroplasties. Knee Surg Sports Traumatol Arthrosc. 2019 Jul;27(7):2322-7.
438	21.	Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on
439		Periprosthetic Joint Infection. Bone Joint J. 2013 Nov;95-B(11):1450-2.
440	22.	Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, et al. The 2018
441		Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and
442		Validated Criteria. J Arthroplasty. 2018 May;33(5):1309-1314.e2.
443	23.	Ghanem E, Heppert V, Spangehl M, Abraham J, Azzam K, Barnes L, et al. Wound
444		management. J Orthop Res Off Publ Orthop Res Soc. 2014 Jan;32 Suppl 1:S108-19.
445	24.	Xu H, Yang J, Xie J, Huang Z, Huang Q, Cao G, et al. Efficacy and safety of
446		intrawound vancomycin in primary hip and knee arthroplasty. Bone Joint Res. 2020
447		Nov;9(11):778–88.
448	25.	Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical
449		Phenotypes. Clin Biochem Rev. 2016 May;37(2):85–98.

450 26. Kang DG, Holekamp TF, Wagner SC, Lehman RAJ. Intrasite vancomycin powder for
451 the prevention of surgical site infection in spine surgery: a systematic literature
452 review. Spine J. 2015 Apr;15(4):762–70.

- Tubaki VR, Rajasekaran S, Shetty AP. Effects of using intravenous antibiotic only
 versus local intrawound vancomycin antibiotic powder application in addition to
 intravenous antibiotics on postoperative infection in spine surgery in 907 patients.
 Spine (Phila Pa 1976). 2013 Dec;38(25):2149–55.
- 457 28. Heckmann ND, Mayfield CK, Culvern CN, Oakes DA, Lieberman JR, Della Valle CJ.
 458 Systematic Review and Meta-Analysis of Intrawound Vancomycin in Total Hip and
 459 Total Knee Arthroplasty: A Call for a Prospective Randomized Trial. J Arthroplasty.
 460 2019 Aug;34(8):1815–22.
- 461 29. Koutalos AA, Drakos A, Fyllos A, Doxariotis N, Varitimidis S, Malizos KN. Does
 462 Intra-Wound Vancomycin Powder Affect the Action of Intra-Articular Tranexamic
- 463 Acid in Total Joint Replacement? Microorganisms. 2020 May;8(5).
- 464 30. Yavuz IA, Oken OF, Yildirim AO, Inci F, Ceyhan E, Gurhan U. No effect of
 465 vancomycin powder to prevent infection in primary total knee arthroplasty: a
 466 retrospective review of 976 cases. Knee Surg Sports Traumatol Arthrosc. 2020
 467 Sep;28(9):3055–60.
- 468 31. Khatri K, Bansal D, Singla R, Sri S. Prophylactic intrawound application of
 469 vancomycin in total knee arthroplasty. J Arthrosc Jt Surg [Internet]. 2017;4(2):61–4.
 470 Available from:
- 471 https://www.sciencedirect.com/science/article/pii/S2214963517300330
- Winkler C, Dennison J, Wooldridge A, Larumbe E, Caroom C, Jenkins M, et al. Do
 local antibiotics reduce periprosthetic joint infections? A retrospective review of 744
 cases. J Clin Orthop trauma. 2018 Mar;9(Suppl 1):S34–9.
- 475 33. Dial BL, Lampley AJ, Green CL, Hallows R. Intrawound Vancomycin Powder in
 476 Primary Total Hip Arthroplasty Increases Rate of Sterile Wound Complications. Hip
 477 pelvis. 2018 Mar;30(1):37–44.
- 478 34. Xu X, Zhang X, Zhang Y, Chen C, Yu H, Xue E. Role of intra-wound powdered
 479 vancomycin in primary total knee arthroplasty. Orthop Traumatol Surg Res. 2020
 480 May;106(3):417–20.
- 481 35. Otte JE, Politi JR, Chambers B, Smith CA. Intrawound Vancomycin Powder Reduces
 482 Early Prosthetic Joint Infections in Revision Hip and Knee Arthroplasty. Surg
 483 Technol Int. 2017 Feb;30:284–9.

484	36.	Patel NN, Guild GN 3rd, Kumar AR. Intrawound vancomycin in primary hip and knee
485		arthroplasty: a safe and cost-effective means to decrease early periprosthetic joint
486		infection. Arthroplast today. 2018 Dec;4(4):479-83.
487	37.	Peng Z, Lin X, Kuang X, Teng Z, Lu S. The application of topical vancomycin powder
488		for the prevention of surgical site infections in primary total hip and knee arthroplasty:
489		A meta-analysis. Orthop Traumatol Surg Res. 2021 Jun;107(4):102741.
490	38.	Wong MT, Sridharan SS, Davison EM, Ng R, Desy NM. Can Topical Vancomycin
491		Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty? A Systematic
492		Review. Clin Orthop Relat Res. 2021 Aug;479(8):1655-64.
493	39.	Hoelen DWM, Tjan DHT, van Vugt R, van der Meer YG, van Zanten ARH. Severe
494		local vancomycin induced skin necrosis. Vol. 64, British journal of clinical
495		pharmacology. England; 2007. p. 553-4.
496		
497		
498		
499		
500		
501		
502		
503		
504		
505		
506		
507		
508		
509		
510		
511		
512		
513		
514		
515		
516		
517		

518 List of Tables

Characteristics	Study Group	Control Group	p-value
	N=507	N=515	
Mean Age (SD)	61.7 (7.52)	61.4 (7.39)	0.520 *
Mean BMI (SD)	28.5 (4.49)	28.4 (4.52)	0.722 *
Mean Pre-op Haemoglobin	12.2 (1.41)	12.3 (1.33)	0.243 *
(SD)			
Mean Post-op Haemoglobin	10.3 (1.34)	10.4 (1.24)	0.215 *
(SD)			
Mean drop in Haemoglobin	-1.96 (1.143)	-1.91 (1.111)	0.478 *
(SD)			
Mean ASA (SD)	2.02 (0.143)	2.01 (0.186)	0.336 *
Mean Tourniquet Time (min)	70.2 (16.35)	71.1 (21.91)	0.457 *
(SD)			
Smoking N (%)	58 (11.44)	60 (11.65)	0.916 *
CCI Risk Classification			
Mild risk	324 (63.9)	330 (64.07)	
			0.278 †
Moderate risk	156 (30.76)	164 (31.84)	
High Risk	27 (5.34)	21 (4.09)	
Mean CCI (SD)	2.3 (1.15)	2.2 (1.14)	0.163 *
Gender Female N (%)	360 (71)	358 (69.51)	
Male N (%)	147 (29)	157 (30.49)	0.586 †
Diabetics N (%)	170 (33.53)	161 (31.26)	0.438 †
Hypothyroidism N (%)	85 (16.76)	92 (17.86)	0.642 †
CKD N (%)	2 (0.39)	4 (0.77)	0.424 †
ASA N (%) ASA I	6 (1.2)	10 (1.94)	
N (%) ASA II	491 (96.84)	492 (95.53)	0.220 †
N (%) ASA III	10 (1.96)	13 (2.53)	

519

* independent samples t-test, † Chi-square test

520 Table.1. *Demographic and Baseline Characteristics of the study population*

	Study Group	Control Group	p-value
	N(%)	N(%)	
Major Complications			
SSI N (%)	1	2	
PJI (DAIR)	1	3	0.264 †
Periprosthetic fracture	2	0	
Minor Complications			
Persistent Wound Drainage	43 (8.48)	26 (5.04)	<u>0.010</u> †
Stitch Abscess	20 (3.94)	13 (2.52)	
Delayed stitch removal (>3 weeks)	36 (7.1)	36 (6.99)	0.945 †
Medical Complications			
Septic shock and MODS	0	1	NS †
DVT	0	1	
CVA	0	0	
Acute kidney injury/	0	0	
Nephrotoxicity			
Cardiac complications	0	0	

†Chi-square test

Table 2: *Summary of complications in the study population*

524	
525	
526	
527	
528	
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	

Patient	Age Range	CCI	Time to Second surgery (weeks)	Culture report	Diagnosis	Treatment
Study						
1	51-60	1	5	No growth	PJI	DAIR
2	51-60	1	6	No growth	SSI	Debridement and secondary suturing
Control						
1	61-70	4	13	S. aureus	РЛ	 DAIR Two-stage revision
2	61-70	2	20	No growth	PJI	DAIR
3	61-70	2	6	No growth	РЛ	DAIR
4	61-70	2	12	S. epidermidis	SSI	Debridement and secondary suturing
5	61-70	3	16	No growth	SSI	Debridement and secondary suturing Septic shock and MODS

Table 3: Clinical summary of PJI and SSI cases

	Study Group	Control Group	p-value
	n (%)	n (%)	
Number of Diabetics	170 (33.5)	161 (31.26)	0.444 †
Mean HbA1C (SD)	6.6 (2.04)	6.8 (1.95)	0.109 *
DM-CCI grading			
Mild	61 (35.9)	61 (37.9)	0.439 †
Moderate	88 (51.8)	87 (54.0)	
Severe	21 (12.4)	13 (8.1)	
Mean CCI (SD)	3.0 (1.03)	2.9 (1.14)	0.141 *
	Infectio	on rates	
Major Complications			
SSI	0	0	0.160 †
PJI (DAIR)	0	2	
Minor Complications			
Maceration, n (%)	9 (5.3)	6 (3.5)	0.329 †
Stitch Abscess, n (%)	15 (9.3)	4 (2.5)	
Delayed staple removal	36 (7.5)	36 (7.3)	0.942 †
(>3 weeks) n (%)			
	1	I	

* independent samples t-test, † Chi-square test

Table 4: *Sub-group analysis of outcomes in the high-risk diabetic patients in both groups*

	Study Group	Control Group	p-value
	Minor complications	Minor complications	
	n (%)	n (%)	
BMI grading			
Normal	16 (26.2)	11 (29.7)	
Overweight	24 (39.3)	16 (43.3)	
Class I Obese	15 (24.6)	5 (13.5)	0.759 †
Class II Obese	5 (8.2)	4 (10.8)	
Class III Obese	1 (1.6)	1 (2.7)	
Total	61 (100.0)	37 (100.0)	

† Chi-square test

Table 5: Sub-group analysis of minor complications based on the classification of obesity

	Study Group	Control Group	p-value
	Major complications	Major complications	
	n (%)	n (%)	
BMI grading			
Normal	1 (25.0)	0 (0.0)	
Overweight	2 (50.0)	3 (60.0)	
Class I Obese	1 (25.0)	2 (40.0)	0.507 †
Class II Obese	0 (0.0)	0	
Class III Obese	0 (0.0)	0	

† Chi-square test

Table 6: Sub-group analysis of major complications based on the classification of obesity

ENROLMENT

